Management of HLH Post-Dengue Infection
For dengue-associated HLH, initiate treatment with high-dose corticosteroids (dexamethasone 10 mg/m² daily) for 3-4 days as first-line therapy, reserving etoposide only for severe presentations with imminent organ failure. 1
Clinical Recognition
Suspect dengue-associated HLH in any severe dengue case, particularly when you observe:
- Prolonged or recurrent fever persisting >7 days beyond typical dengue timeline
- Persistent cytopenias (thrombocytopenia, neutropenia, anemia) after resolution of the critical phase
- Anemia without evidence of intravascular hemolysis or massive bleeding
- Hepatosplenomegaly developing during or after dengue infection 1, 2
Diagnosis requires fulfilling ≥5 of 8 HLH-2004 criteria, supplemented by:
- Hyperferritinemia (typically >3000 ng/mL)
- Hypertriglyceridemia (>314 mg/dL)
- Bone marrow evidence of hemophagocytosis 3, 2
Treatment Algorithm
Mild-to-Moderate Disease (No Organ Failure)
Start with corticosteroid monotherapy:
- Dexamethasone 10 mg/m² daily for 3-4 days initially 1
- If responding, taper over 4-8 weeks 2, 4
- Alternative: Prednisolone 1-2 mg/kg daily 5
Add IVIG if inadequate response:
- 1.6 g/kg divided over 2-3 days 5
This conservative approach is justified because dengue-associated HLH often responds favorably to steroids alone, with documented complete remissions using steroid monotherapy 1, 4. One case achieved complete remission with just 4 weeks of steroid therapy, remaining disease-free 3 years later 4.
Severe Disease (Imminent Organ Failure)
Immediate etoposide is indicated when:
- Rapid clinical deterioration
- Multi-organ dysfunction developing
- Refractory to initial corticosteroid therapy 5
Regimen:
- Dexamethasone 10 mg/m² PLUS modified-dose etoposide
- Reduce etoposide dose if renal impairment present
- Weekly reassessment to determine continuation need 5
Critical Monitoring Parameters
Track these markers to guide treatment duration and intensity:
- Ferritin and sCD25 levels
- Complete blood counts (resolution of cytopenias)
- Fever pattern (should resolve within days of appropriate therapy)
- Liver function and triglycerides 5
Important Caveats
Infection prophylaxis is mandatory during HLH treatment due to severe immunosuppression:
- Pneumocystis jirovecii prophylaxis
- Antifungal prophylaxis
- Consider antiviral prophylaxis given T-cell depletion 5
Distinguish from dengue shock syndrome: The clinical overlap between dengue-associated HLH and dengue sepsis/shock can lead to misdiagnosis 3. HLH should be suspected when fever persists beyond the typical dengue timeline despite supportive care, and when cytopenias worsen rather than improve after the critical phase.
Prognosis varies significantly: While some patients respond excellently to steroids alone 1, 4, dengue-associated HLH can be fatal even with aggressive treatment, particularly when complicated by shock syndrome, severe liver dysfunction, or bleeding complications 6. The key is early recognition—delayed diagnosis substantially worsens outcomes 2.
Avoid overtreatment: Unlike EBV-HLH which often requires the full HLH-94 protocol with 8 weeks of etoposide 5, dengue-associated HLH frequently responds to short steroid courses. Reserve etoposide for truly severe cases, as the infection-triggered nature of dengue-HLH means the trigger is self-limited once the viral infection resolves 5, 1.